| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.038 | 0.6 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |